Non-Dilutive vs VC: How to Combine Both
Use grants to de-risk milestones and improve round terms, while keeping your narrative consistent across audiences.
The simple model
VC funds speed and market capture. Non-dilutive funds proof and de-risking. Together, they create momentum: proof → better terms → more speed.
The best-funded biotechs don't choose between equity and grants, they sequence them strategically to maximize runway while minimizing dilution.
A practical sequence
Pre-Seed: Pick 1–2 foundations aligned with your disease area. These are often faster to apply for and can provide early validation.
Seed: NIH/NSF + a programmatic agency. SBIR Phase I is designed exactly for this stage, use it to fund the experiments that make your Series A story compelling.
Series A: Scale with larger calls and public-private initiatives. BARDA, ARPA-H, and large foundation programs can provide $2–10M+ in non-dilutive capital.
Why this matters for your cap table
A single $2M SBIR award at the seed stage can reduce the equity you need to raise by 20–30%. Over multiple rounds, the compounding effect on founder ownership is dramatic.
More importantly, grant awards signal to VCs that external experts have validated your science, which improves term sheets.
The key insight
Non-dilutive funding isn't a substitute for venture capital. It's a complement that makes every equity dollar go further and every negotiation stronger.